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Background
Pulmonary hypertension (PH) due to vasoconstriction
and occlusion of the pulmonary microvasculature is a
characteristic feature of the acute respiratory distress syn-
drome (ARDS). Inhaled nitric oxide (NO) selectively
dilates the pulmonary vasculature by activating soluble
guanylate cylase (sGC). Bay 41-2272 a novel sGC stimula-
tor not only activates sGC NO independently, but also
leads to synergistic effects when combined with NO.
Because contradictory results of a number of experimental
studies dealing with the effects of iNO in acute lung injury
and the uncertain efficacy of iNO in the treatment of
ARDS, we evaluated the effects of iNO and BAY 41-2272
in a model of acute lung injury. METHODS: Acute lung
injury (ALI) was induced by i.v. injection of oleic acid
(OA). In the first treatment group iNO (2 ppm) was
administered continuously after ALI. In the second group,
BAY 41-2272 (100 µg/kg) was infused for 10 min directly
after injection of OA. In the third group, iNO and BAY 41-
2272 were combined.
Results
iNO was not able to improve OA induced lung injury. The
intravenous administration of BAY 41-2272 alone slightly
decreased pulmonary artery pressure (PAP) with no sys-
temic hemodynamic effects but failed to improve gas
exchange. The combined administration of iNO and BAY
41-2272 clearly lowered PAP again without affecting sys-
temic arterial pressures but improved arterial oxygenation
and intrapulmonary shunting.
Conclusion
This study showed that combined administration of BAY
41-2272 with iNO leads to selective pulmonary vasodila-
tation which is associated with an improvement of gas
exchange. Due to the known mechanism of action of the
two substances, this effect is probably mediated by an
increase of local cGMP concentrations in well ventilated
lung regions.
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